HROW · Harrow, Inc. · Stock research

Current Thesis

Harrow is a commercial-stage ophthalmology pharma whose stock trades almost entirely on one question: does the second-half revenue ramp management is promising actually print. Q1 2026 (reported 2026-05-12) landed at $44.2M revenue against $52.55M consensus — a ~16% miss that dropped shares ~26% to a mid-May low near $33.99. Management pinned the gap on a one-time ~$8M VEVYE gross-to-net true-up rather than softening demand and reaffirmed full-year guidance of $350–365M revenue and $80–100M adjusted EBITDA, with Q2 guided to $71–81M. That Q2 figure implies a 60–80% sequential jump off Q1 and is the number that validates or breaks the whole guide. Since May the tape has recovered hard — VERKAZIA relaunched 2026-06-10, BYOOVIZ launched 2026-07-01, ASRS 2026 clinical data landed mid-July, and the stock ran to ~$46.65 intraday on 2026-07-17 before settling near $44.45 by 2026-07-21. That is roughly a 40% recovery off the May low front-running a print that does not arrive until roughly 2026-08-11. This is a sentiment-led drift into an unconfirmed binary, not a momentum leg with results behind it.

Bullish and bearish views on Harrow, Inc.

The model's bull view on Harrow, Inc. (HROW), in brief: Underlying demand accelerated even as reported Q1 revenue missed. The bear view: Q1 was a real miss and the loss is widening. Both cases follow in full.

Bull Case

• Underlying demand accelerated even as reported Q1 revenue missed. On the 2026-05-12 Q1 call VEVYE posted record prescriptions, passed XIIDRA on monthly TRx and reached ~14% dry-eye share; Tier-1 accounts grew scripts ~170% sequentially with NRx +25% / TRx +11% QoQ. The headline miss traced to the ~$8M gross-to-net adjustment while prescription volume grew.
• Portfolio breadth widened through Q2. IHEEZO unit demand rose +18% YoY and TRIESENCE +136% YoY in Q1 2026. VERKAZIA relaunched 2026-06-10 for pediatric VKC (+7.3% session), and BYOOVIZ — an FDA-interchangeable Lucentis biosimilar from Samsung Bioepis — began US commercial sales 2026-07-01, with US rights to OPUVIZ (an EYLEA biosimilar) also secured, adding a retinal anti-VEGF leg to the front-of-eye franchise.
• Clinical validation stacked ahead of the print. At ASRS 2026 (2026-07-20) Samsung Bioepis and Harrow presented interim post-marketing safety data showing SB11 (BYOOVIZ) comparable to Lucentis, and Harrow presented three studies supporting IHEEZO and BYOOVIZ. Scientific reinforcement of the retinal story, though not a Q2 top-line driver.
• Analyst tape supportive and reiterated close to the catalyst. BTIG reiterated Buy with a $63 target on 2026-07-21; the average target sits ~$67.75 (range $59–88) against a ~$44–46 quote, with a Strong Buy consensus. Upside is real only if August validates the ramp.
• Reaffirmed guide implies a steep H2 inflection. FY2026 revenue $350–365M and adjusted EBITDA $80–100M, Q2 $71–81M, VEVYE alone guided above $100M annually (all reaffirmed 2026-05-12). Clearing the Q2 bar re-rates a name the Street already rates Strong Buy.

Bear Case

• Q1 was a real miss and the loss is widening. Net loss widened to $27.6M (from $17.8M YoY), EPS -$0.74, adjusted EBITDA -$12.7M in Q1 2026 (2026-05-12). Cash is burning into the ramp the company must now deliver.
• The Q2 bar is the trap. $71–81M off a $44.2M base is a figure management has to hit; a print near the low end or below resets the FY guide and the multiple. The report is roughly 2–3 weeks out (~2026-08-11).
• The rally front-ran the print. From the ~$34 May low to ~$46.65 intraday on 2026-07-17, the stock is back in the upper half of its $28.54–$54.85 52-week range on sentiment, not results. Biosimilars like BYOOVIZ are low-margin and competitive, and the ASRS data is scientific rather than a Q2 revenue mover — the price has priced confidence the numbers have not yet earned.
• A second gross-to-net hit would signal something structural. If another VEVYE GTN adjustment shows up in Q2, it points to a rebate/coverage problem rather than a one-time item — the single most important line to read in the release.
• Leverage amplifies any reset. Harrow carries meaningful senior-note debt against negative trailing adjusted EBITDA, a rate- and execution-sensitive balance sheet where a guide cut hits harder than the revenue delta alone.

Setup & Price Structure

The chart is a recovery working into resistance ahead of a binary, not a confirmed trend breakout. After the 2026-05-12 print HROW fell ~26% and bottomed near $33.99 in mid-May, built a June–July base in the low-$40s, then drifted up to ~$46.65 intraday on 2026-07-17 before easing to ~$44.45 by 2026-07-21. The move carried the stock into the upper third of its 52-week range, with the $54.85 high the next overhead line and the June–July shelf near $38 the structural floor below spot; the $33.99 May reaction low is the deeper support. The rally has been a low-volume sentiment drift into ASRS headlines and analyst reiterations rather than a volume-backed thrust, and it stalls under prior highs the way a name marking time into an event does. The relevant read is not the slope but the gap risk: the setup sits directly on top of a print that can move the stock 20–40% overnight, which makes fresh entries in the three sessions ahead of ~2026-08-11 a gamble on a number with an edge.

Catalyst Calendar (next 30 days)

• ~2026-08-11 (est.): Q2 2026 financial results — the binary. $71–81M revenue guide versus $44.2M Q1 actual, a 60–80% sequential jump. Watch VEVYE gross-to-net (recurrence of the Q1 ~$8M item), the FY $350–365M reaffirmation, and adjusted-EBITDA trajectory. Avoid fresh entries in the three trading days ahead — binary gap risk.

Elapsed catalysts

• Through late July–early August: BYOOVIZ (launched 2026-07-01) and OPUVIZ commercial-ramp datapoints; any follow-through coverage on the 2026-07-20 ASRS SB11/IHEEZO presentations. (passed 15d ago)
• Ongoing: additional sell-side notes clustering around the print after the 2026-07-21 BTIG $63 reiteration; any pre-announcement or guidance update would front-run the report. (passed 14d ago)

What Would Change Our Mind

The recovery thesis breaks on a weekly close below $38, which loses the June–July recovery base and puts the mid-May $33.99 reaction low back in play. The fundamental break is the ~2026-08-11 Q2 print landing at or below the $71M guide low end and forcing a full-year revenue-guide reset — that turns the "one-time GTN" narrative into a demand problem and removes the reason the Street carries $59–88 targets. A second VEVYE gross-to-net adjustment in the release is the same signal even if the headline number squeaks in. Conversely, a Q2 print inside or above $71–81M with the FY guide reaffirmed or raised validates the ramp and re-rates the multiple toward the analyst band; that is the outcome the pre-print drift is betting on, and it is unconfirmed until the number lands. Until then this is a show-me event, and the disciplined stance is to stand aside into the print rather than pay up for a guess.

Correlation Notes

HROW is an idiosyncratic special situation with low beta to the AI/semis complex driving the broad tape; its dominant driver is a single company-specific revenue print. Secondary correlations run through small-cap specialty-pharma risk appetite and, via the leveraged balance sheet, interest-rate sensitivity — a tightening regime pressures the equity independent of the operating story. Product-level read-throughs matter more than index moves: dry-eye competitive dynamics (AbbVie's XIIDRA, which VEVYE passed on monthly TRx) and anti-VEGF biosimilar pricing (Lucentis/EYLEA references for BYOOVIZ/OPUVIZ) inform the franchise. The Q2 catalyst is uncorrelated to macro — it prints on a fixed date and resolves on the company's own numbers.

Correlation Notes (addendum)

Peer ophthalmology names moving on their own commercial updates offer little predictive signal for the ~2026-08-11 print; position the read around the release, not the sector tape.